[1]王国珍,汤旭东,吴玉云,等.肝素酶特异性细胞毒T淋巴细胞表位多抗原肽负载的树突状细胞疫苗体外抗肿瘤免疫效应研究[J].第三军医大学学报,2011,33(08):761-764.
 Wang Guozhen,Tang Xudong,Wu Yuyun,et al.Study on in vitro antitumor immune responses elicited by dendritic cells pulsed with heparanase multiple antigen peptides containing cytotoxic T lymphocyte epitopes[J].J Third Mil Med Univ,2011,33(08):761-764.
点击复制

肝素酶特异性细胞毒T淋巴细胞表位多抗原肽负载的树突状细胞疫苗体外抗肿瘤免疫效应研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
33卷
期数:
2011年第08期
页码:
761-764
栏目:
论著
出版日期:
2011-04-30

文章信息/Info

Title:
Study on in vitro antitumor immune responses elicited by dendritic cells pulsed with heparanase multiple antigen peptides containing cytotoxic T lymphocyte epitopes
作者:
王国珍汤旭东吴玉云李宁李长珠陈陵房殿春杨仕明
第三军医大学西南医院全军消化病研究所
Author(s):
Wang Guozhen Tang Xudong Wu Yuyun  Li Ning  Li Changzhu Chen Ling  Fang Dianchun Yang Shiming
Institute of Gastroenterology,  Southwest Hospital,  Third Military Medical University,  Chongqing,  400038, China
关键词:
肝素酶CTL表位多抗原肽树突状细胞肿瘤疫苗
Keywords:
heparanaseCTL epitopesmultiple antigen peptidedendritic cellstumor vaccine
分类号:
R73-362;R392.13;R392.2
文献标志码:
A
摘要:
目的    研究肝素酶(heparanase,Hpa)细胞毒T淋巴细胞(cytotoxic T lymphocyte,CTL)表位多抗原肽(multiple antigen peptides,MAP)疫苗能否诱导更强的Hpa特异性CTL反应。    方法    HLA-A2.1限制性肝素酶CTL表位多抗原肽负载正常人外周血来源(peripheral blood mononuclear cell,PBMC)树突状细胞(dendritic cell,DC),诱导CTL,采用4 h标准51Cr释放实验检测上述CTL对不同肿瘤细胞的免疫杀伤效应;采用ELISPOT实验检测效应细胞分泌IFN-γ的能力。    结果    肝素酶CTL表位MAP疫苗诱导的CTL对Hpa阳性且HLA-A2.1匹配的KATO-Ⅲ胃癌细胞、U2OS骨肉瘤细胞、SW480结肠癌细胞具有杀伤效应,且其杀伤效应强于相应的单肽,在最大效应细胞/靶细胞(effector/target, E/T) 时高出率均大于16%;其对HLA-A2.1阴性的HepG2肝癌细胞和Hpa阴性的MCF-7乳腺癌细胞不具有杀伤效应,但是对MCF-7/Hpa乳腺癌细胞和HepG2/HLA-A2肝癌细胞具有杀伤效应,且其杀伤效应强于相应的单肽,在最大E/T时高出率均大于18%;其对自体淋巴细胞和DC 不具有杀伤效应。另一方面人肝素酶CTL表位MAP疫苗诱导的IFN-γ分泌水平强于相应的单肽。    结论    肝素酶CTL表位MAP疫苗能激发较相应单肽更强的特异性和非特异性抗肿瘤效应。
Abstract:
Objective    To study whether the multiple antigen peptides (MAPs) of heparanase (Hpa) can elicit stronger Hpa-specific cytotoxic T lymphocyte (CTL) responses against various tumors in vitro.     Methods    Dendritic cells (DCs) were pulsed with HLA-A2.1-restricted Hpa MAPs and Hpa single peptides to induce Hpa-specific CTLs. The lysis of KATO-Ⅲ gastric cancer cells, U2OS osteogenic sarcoma cells, SW480 colon cancer cells, HepG2 liver cancer cells, MCF-7 breast cancer cells, HepG2/HLA-A2.1 liver cancer cells, and MCF-7/Hpa breast cancer cells by Hpa-specific CTLs was examined by 4-h standard 51Cr release assay. The IFN-γ production of the effector cells was tested with ELISPOT.     Results    Compared with those induced by Hpa single peptides, the CTLs induced by Hpa MAPs had stronger specific lysis effects on Hpa- and HLA-A2.1-positive tumor cells (KATO-Ⅲ, U2OS, and SW480), by more than 16% at the maximum effector/target (E/T) ratio. Neither Hpa-negative MCF-7 cells nor HLA-A2.1-negative HepG2 cells were lysed by the CTLs. The effector cells induced by Hpa MAPs, however, could lyse HepG2/HLA-A2.1 cells (HLA-A2.1-positive) and MCF-7/Hpa cells (Hpa-positive), and had stronger specific lysis effects than those induced by Hpa single peptides, by more than 18% at the maximum E/T ratio. Hpa MAPs could not elicit lysis of auto-logous lymphocytes and DCs. Compared with Hpa single peptides, Hpa MAPs could increase the frequency of IFN-γ-producing T cells.     Conclusions    This study shows that Hpa MAPs can elicit stronger specific and nonspecific antitumor immune responses by Hpa-specific CTLs. 

相似文献/References:

[1]陈婷,万瑛,汤旭东,等.人肿瘤转移相关抗原肝素酶HLA-A2.1限制性CTL表位的预测及初步鉴定[J].第三军医大学学报,2007,29(22):2120.
 CHEN Ting,WAN Ying,TANG Xu-dong,et al.Prediction and peptide binding assay of HLA-A2.1-restricted CTL epitope from heparanase[J].J Third Mil Med Univ,2007,29(08):2120.
[2]陈陵,李志宏,杨仕明,等.人肝素酶基因正反义荧光真核表达载体的构建及肝癌细胞转染[J].第三军医大学学报,2006,28(01):47.
[3]韩静,张浩,杨鹰,等.肝素酶、bFGF在卵巢癌中的表达及与其血管生成的关系[J].第三军医大学学报,2009,31(05):434.
 HAN Jing,ZHANG Hao,YANG Ying,et al.Relationship of heparanase and bFGF expressions with angiogenesis in human ovarian carcinoma: report of 41 cases[J].J Third Mil Med Univ,2009,31(08):434.
[4]李宁,陈伟,张亚飞黎川,等.抗肿瘤转移肝素酶特异性抗体的筛选及鉴定[J].第三军医大学学报,2011,33(08):771.
 Li Ning,Chen Wei,Zhang Yafei,et al.Screening and identification of specific anti-heparanase monoclonal antibody inhibiting tumor metastasis[J].J Third Mil Med Univ,2011,33(08):771.
[5]王晴,吴玉章.SARS冠状病毒E蛋白HLA-A~*0201限制性CTL表位的预测[J].第三军医大学学报,2004,26(12):0.[doi:10.16016/j.1000-5404.2004.12.013 ]
 WANG Qing,WU Yu zhang.[J].J Third Mil Med Univ,2004,26(08):0.[doi:10.16016/j.1000-5404.2004.12.013 ]
[6]王莉,吴玉章,石统东,等.穿膜肽HIV-Tat49-57和CTL表位融合多肽疫苗的初步免疫学效应研究[J].第三军医大学学报,2002,24(10):0.[doi:10.16016/j.1000-5404.2002.10.014 ]
 WANG Li,WU Yu zhang,SHI Tong dong,et al.[J].J Third Mil Med Univ,2002,24(08):0.[doi:10.16016/j.1000-5404.2002.10.014 ]
[7]王莉,吴玉章,林治华,等.分子模拟在筛选HLA-A2.1高亲和性MART-1 CTL表位中的应用研究[J].第三军医大学学报,2002,24(10):0.[doi:10.16016/j.1000-5404.2002.10.017 ]
 WANG Li,WU Yu zhang,LIN Zhi hua,et al.[J].J Third Mil Med Univ,2002,24(08):0.[doi:10.16016/j.1000-5404.2002.10.017 ]
[8]王莉,吴玉章.MART-1HLA-A2限制性CTL表位的预测[J].第三军医大学学报,2000,22(10):0.[doi:10.16016/j.1000-5404.2000.10.006 ]
 WANG Li,WU Yu zhang.[J].J Third Mil Med Univ,2000,22(08):0.[doi:10.16016/j.1000-5404.2000.10.006 ]
[9]周吉军,吴玉章,王祥智,等.O-糖基化HBVPre-S2CTL表位分子模建及免疫学活性研究[J].第三军医大学学报,2000,22(10):0.[doi:10.16016/j.1000-5404.2000.10.016 ]
 ZHOU Ji jun,WU Yu zhang,WANG Xiang zhi,et al.[J].J Third Mil Med Univ,2000,22(08):0.[doi:10.16016/j.1000-5404.2000.10.016 ]
[10]赵建平,吴玉章.CTL表位预测的方法学进展[J].第三军医大学学报,2000,22(10):0.[doi:10.16016/j.1000-5404.2000.10.026 ]

更新日期/Last Update: 2011-04-13